New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
07:05 EDTMDCOThe Medicines Co. announces FDA BLA acceptance for Fibrocaps,
The Medicines Co. announced that the U.S. Food and Drug Administration has accepted the filing of a biologic license application for the investigational hemostatic agent Fibrocaps, a dry powder formulation of fibrinogen and thrombin being developed to aid in hemostasis during surgery, where control of mild or moderate bleeding by conventional means is ineffective or impractical. The FDA action date for Fibrocaps is January 31, 2015.
News For MDCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2015
08:30 EDTMDCOBioNJ to hold a summit
Subscribe for More Information
October 6, 2015
17:16 EDTMDCOThe Medicines Co., SymBio Pharmaceuticals enter strategic partnership in Japan
Subscribe for More Information
October 5, 2015
07:31 EDTMDCOThe Medicines Co. ALN-PCSsc 'a potential game changer,' says RBC Capital
After examining surveys and speaking with experts, RBC Capital says that the uptake of The Medicines Co's ALN-PCSsc treatment has been strong among anti-PCSK9 patients, reaching 20%-30%. The firm estimates that the company could conservatively generate $9B-$18B in revenue from the drug. It believes that the product is "a potential game changer and valuation driver" for the company. RBC keeps a $46 price target and Outperform rating on the shares.
October 1, 2015
07:05 EDTMDCOMedicines Company says BARDA exercises option on Carbavance pact
The Medicines Company announced that Rempex Pharmaceuticals, a wholly owned subsidiary, has been awarded the next option on a contract by the Biomedical Advanced Research and Development Authority, or BARDA, to support the development of CARBAVANCE. CARBAVANCE is the combination of a carbapenem antibiotic with a novel beta-lactamase inhibitor that is targeted for treatment of multi-drug resistant gram-negative infections, including those due to carbapenem-resistant Enterobacteriaceae. The cost-share contract with BARDA was initiated in 2014 and extends over 5 years. The award of this third option brings the total commitment from BARDA to $53.8M. If all options are exercised in the contract, it would bring the total value of the award to approximately $90M.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use